Blue Sail Medical (002382.SZ) announced its performance forecast for H1 2024, with an estimated net income loss of RMB 0.2-0.14 billion attributable to the company's shareholders, up 15.47%-40.83% year-on-year. After deducting non-recurring gains and losses, the net income loss is estimated to be RMB 0.23-0.17 billion, up 27.26%-46.24% year-on-year; basic earnings per share are expected to be a loss of RMB 0.20-0.14 per share.
The company's Protective Business Unit continued to operate at a loss from January to June 2024, but the loss was significantly reduced compared to the same period last year, and it turned a profit in the second quarter. Despite the industry capacity still being cleared gradually in the first half of 2024, the Protective Business Unit spared no effort in developing new customers and seizing market orders, actively promoting technological innovation and cost reduction, achieving a significant increase in revenue, as well as further improvement in production and sales volume and market share.
The company's Cardiovascular and Cerebrovascular Business Unit achieved sales revenue of approximately RMB 0.57 billion from January to June 2024, a year-on-year increase of approximately 12%, and continued its growth trend; the gross margin further increased compared to the same period last year, and the extent of loss further narrowed.
The company's Nursing Business Unit had a profit of approximately RMB 14 million from January to June 2024. While stabilizing stock business, it continued to develop the domestic market, promote automation to reduce costs and increase efficiency, and further improved the gross margin compared to the same period in 2023.